Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
Status:
Completed
Trial end date:
2018-11-25
Target enrollment:
Participant gender:
Summary
The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect
depositions of a protein, called tau, in the brains of people with a mutation in the tau gene
that causes deposition of the protein, and in people without the mutation. Up to three
18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT
mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.
Phase:
Phase 2
Details
Lead Sponsor:
Columbia University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)